Literature DB >> 3143267

Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance.

R C Tripathi1, J K Park, B J Tripathi, C B Millard.   

Abstract

By using an enzyme-linked immunosorbent assay, we detected a significant amount of tissue plasminogen activator (0.8 +/- 0.17 ng/ml) in the aqueous humor of ten normal human eyes. It was also identified on Western blot analysis. The ratio of tissue plasminogen activator to total protein in aqueous humor was about 30 times greater than the ratio of tissue plasminogen activator to total protein in plasma. There was evidence that at least some of the tissue plasminogen activator in the aqueous humor was synthesized locally by the structures bordering the anterior chamber of the eye. Tissue plasminogen activator may be a useful therapeutic modality in clinical conditions of delayed dissolution of fibrin in the eye.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143267     DOI: 10.1016/0002-9394(88)90707-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.

Authors:  Rosana Gerometta; Sandeep Kumar; Shaily Shah; Larry Alvarez; Oscar Candia; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-03       Impact factor: 4.799

3.  Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.

Authors:  Thomas Bertelmann; Marta Spychalska; Laura Kohlberger; Stefan Strodthoff; Michael Witteborn; Nadia Kicova; Ulrich Sachs; Sebastian Irle; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-12       Impact factor: 3.117

Review 4.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

5.  Plasminogen activators promote excitotoxicity-induced retinal damage.

Authors:  Raghuveer S Mali; Mei Cheng; Shravan K Chintala
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

6.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

7.  Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.

Authors:  H Siatiri; A H Beheshtnezhad; H Asghari; N Siatiri; S Moghimi; N Piri
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 8.  Extracellular matrix turnover and outflow resistance.

Authors:  Kate E Keller; Mini Aga; John M Bradley; Mary J Kelley; Ted S Acott
Journal:  Exp Eye Res       Date:  2008-12-06       Impact factor: 3.467

9.  Spontaneous intraocular hemorrhage in rats during postnatal ocular development.

Authors:  Katsuhiro Inagaki; Hiroyasu Koga; Kazuyoshi Inoue; Katsushi Suzuki; Hiroetsu Suzuki
Journal:  Comp Med       Date:  2014-02       Impact factor: 0.982

10.  Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep.

Authors:  Oscar A Candia; Rosana M Gerometta; John Danias
Journal:  Exp Eye Res       Date:  2014-10-07       Impact factor: 3.467

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.